Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

The new small molecule tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs.

Soncini D, Orecchioni S, Ruberti S, Minetto P, Martinuzzi C, Agnelli L, Todoerti K, Cagnetta A, Miglino M, Clavio M, Contini P, Varaldo R, Bergamaschi M, Guolo F, Passalacqua M, Nencioni A, Monacelli F, Gobbi M, Neri A, Abbadessa G, Eathiraj S, Schwartz B, Bertolini F, Lemoli RM, Cea M.

Haematologica. 2019 Oct 17. pii: haematol.2019.224956. doi: 10.3324/haematol.2019.224956. [Epub ahead of print]

2.

A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia.

Marcolin R, Guolo F, Minetto P, Clavio M, Manconi L, Ballerini F, Carli A, Passannante M, Colombo N, Carminati E, Pugliese G, Tedone E, Contini P, Mangerini R, Kunkl A, Miglino M, Cagnetta A, Cea M, Gobbi M, Lemoli RM.

Leuk Res. 2019 Nov;86:106223. doi: 10.1016/j.leukres.2019.106223. Epub 2019 Sep 6.

PMID:
31557597
3.

Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas.

Manconi L, Coviello E, Canale F, Giannoni L, Minetto P, Guolo F, Clavio M, Marcolin R, Cea M, Cagnetta A, Gobbi M, Miglino M, Ballerini F, Lemoli RM.

Leuk Lymphoma. 2019 Sep 4:1-7. doi: 10.1080/10428194.2019.1658102. [Epub ahead of print]

PMID:
31480933
4.

Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach.

Guolo F, Minetto P, Clavio M, Miglino M, Colombo N, Cagnetta A, Cea M, Marcolin R, Todiere A, Ballerini F, Gobbi M, Lemoli RM.

Br J Haematol. 2019 Sep;186(6):e223-e225. doi: 10.1111/bjh.16116. Epub 2019 Jul 26. No abstract available.

PMID:
31348524
5.

Performance of serum (1,3)-ß-d-glucan screening for the diagnosis of invasive aspergillosis in neutropenic patients with haematological malignancies.

Furfaro E, Giacobbe DR, Del Bono V, Signori A, Guolo F, Minetto P, Clavio M, Ballerini F, Gobbi M, Viscoli C, Mikulska M.

Mycoses. 2018 Sep;61(9):650-655. doi: 10.1111/myc.12787. Epub 2018 Jun 13.

PMID:
29693758
6.

Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.

Minetto P, Guolo F, Clavio M, Kunkl A, Colombo N, Carminati E, Fugazza G, Matarese S, Guardo D, Ballerini F, Di Grazia C, Raiola AM, Cagnetta A, Cea M, Miglino M, Lemoli RM, Gobbi M.

Br J Haematol. 2019 Feb;184(3):457-460. doi: 10.1111/bjh.15106. Epub 2018 Jan 23. No abstract available.

PMID:
29359798
7.

A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis.

Minetto P, Guolo F, Clavio M, Kunkl A, Colombo N, Carminati E, Giannoni L, Ballerini F, Lemoli RM, Gobbi M, Miglino M.

Am J Hematol. 2018 Feb;93(2):E33-E35. doi: 10.1002/ajh.24956. Epub 2017 Nov 17. No abstract available.

8.

Prompt detection of L-asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas.

Guolo F, Ferrari M, Minetto P, Matteo C, Clavio M, Coviello E, Ballerini F, Miglino M, Gobbi M, D'Incalci M, Lemoli RM, Zucchetti M.

Hematol Oncol. 2018 Apr;36(2):498-499. doi: 10.1002/hon.2484. Epub 2017 Oct 20. No abstract available.

PMID:
29052244
9.

Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents.

Cagnetta A, Soncini D, Orecchioni S, Talarico G, Minetto P, Guolo F, Retali V, Colombo N, Carminati E, Clavio M, Miglino M, Bergamaschi M, Nahimana A, Duchosal M, Todoerti K, Neri A, Passalacqua M, Bruzzone S, Nencioni A, Bertolini F, Gobbi M, Lemoli RM, Cea M.

Haematologica. 2018 Jan;103(1):80-90. doi: 10.3324/haematol.2017.176248. Epub 2017 Oct 12.

10.

Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia.

Guolo F, Minetto P, Clavio M, Miglino M, Galaverna F, Raiola AM, Di Grazia C, Colombo N, Pozzi S, Ibatici A, Bagnasco S, Guardo D, Kunkl A, Ballerini F, Ghiggi C, Lemoli RM, Gobbi M, Bacigalupo A.

Haematologica. 2017 Sep;102(9):e348-e351. doi: 10.3324/haematol.2017.167254. Epub 2017 May 11. No abstract available.

11.

Good tolerability of high dose colistin-based therapy in patients with haematological malignancies.

Grignolo S, Tatarelli P, Guolo F, Minetto P, Rivoli G, Guardo D, Del Bono V, Varaldo R, Gualandi F, Ballerini F, Raiola A, Gobbi M, Viscoli C, Mikulska M.

Infection. 2017 Aug;45(4):505-511. doi: 10.1007/s15010-017-1010-7. Epub 2017 Mar 28.

PMID:
28353153
12.
13.

High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.

Guolo F, Minetto P, Clavio M, Miglino M, Di Grazia C, Ballerini F, Pastori G, Guardo D, Colombo N, Kunkl A, Fugazza G, Rebesco B, Sessarego M, Lemoli RM, Bacigalupo A, Gobbi M.

Am J Hematol. 2016 Aug;91(8):755-62. doi: 10.1002/ajh.24391. Epub 2016 Jun 15.

14.

Chronic graft versus host disease as a weapon for treating chronic myelomonocytic leukemia.

Minetto P, Guolo F, Miglino M.

Leuk Res. 2016 Apr;43:49-50. doi: 10.1016/j.leukres.2016.01.005. Epub 2016 Jan 22. No abstract available.

PMID:
26851198
15.

Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes.

Minetto P, Guolo F, Clavio M, De Astis E, Colombo N, Grasso R, Fugazza G, Sessarego M, Lemoli RM, Gobbi M, Miglino M.

Leuk Res. 2015 Aug;39(8):866-73. doi: 10.1016/j.leukres.2015.04.011. Epub 2015 Apr 27.

PMID:
26012361
16.

Bloodstream infections are an improbable cause of positive serum (1,3)-β-D-glucan in hematology patients.

Furfaro E, Mikulska M, Del Bono V, Guolo F, Minetto P, Gobbi M, Ghiso A, Bacigalupo A, Viscoli C.

Clin Vaccine Immunol. 2014 Sep;21(9):1357-9. doi: 10.1128/CVI.00214-14. Epub 2014 Jul 2.

17.

Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.

De Astis E, Clavio M, Raiola AM, Ghiso A, Guolo F, Minetto P, Galaverna F, Miglino M, Di Grazia C, Ballerini F, Marani C, Pastori G, Mitscheunig L, Cruciani F, Lovera D, Varaldo R, Ghiggi C, Lemoli RM, Bacigalupo A, Gobbi M.

Ann Hematol. 2014 Dec;93(12):2011-8. doi: 10.1007/s00277-014-2143-8. Epub 2014 Jul 4.

PMID:
24989345
18.

Cardiovascular adverse events complicating the administration of rituximab: report of two cases.

Passalia C, Minetto P, Arboscello E, Balleari E, Bellodi A, Del Corso L, Molinari E, Ponassi I, Oneto C, Sicbaldi V, Ghio R.

Tumori. 2013 Nov-Dec;99(6):288e-92e. doi: 10.1700/1390.15471.

PMID:
24503806
19.

De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".

Clavio M, Cruciani F, Minetto P, Guolo F, Ballerini F, Marani C, De Astis E, Aquino S, Bergamaschi M, Mitscheunig L, Grasso R, Colombo N, Ghiggi C, Lovera D, Pastori G, Avenoso D, Miglino M, Gobbi M.

Ann Hematol. 2013 Oct;92(10):1309-18. doi: 10.1007/s00277-013-1780-7. Epub 2013 May 18.

PMID:
23686116
20.

Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression.

Miglino M, Colombo N, Grasso R, Marani C, Clavio M, Pica GM, Ballerini F, Ghiggi C, Minetto P, Guolo F, Carella AM, Gobbi M.

Leuk Lymphoma. 2012 Nov;53(11):2214-7. doi: 10.3109/10428194.2012.681658. Epub 2012 May 21.

PMID:
22475129

Supplemental Content

Loading ...
Support Center